What are the recommended treatments for Escherichia coli infections based on infection site and severity?

Treatment for E. Coli Infections

For uncomplicated lower urinary tract infections (the most common E. coli infection), use amoxicillin-clavulanate, nitrofurantoin, or trimethoprim-sulfamethoxazole as first-line therapy 1.

Treatment Algorithm by Infection Site and Severity

Lower Urinary Tract Infections (Cystitis)

First-line options (all Access category):

• Amoxicillin-clavulanate
• Nitrofurantoin
• Trimethoprim-sulfamethoxazole

1

Critical caveat: Plain amoxicillin was removed from WHO recommendations in 2021 after GLASS surveillance data showed 75% median resistance (range 45-100%) in E. coli urinary isolates across 22 countries 1. Never use amoxicillin alone for empiric treatment.

Avoid fluoroquinolones (ciprofloxacin, levofloxacin) for simple cystitis due to resistance concerns and FDA warnings about serious adverse effects on tendons, muscles, joints, nerves, and central nervous system 1. Reserve these for more serious infections where benefits outweigh risks.

Upper Urinary Tract Infections (Pyelonephritis/Prostatitis)

Mild-to-moderate severity:

• First choice: Ciprofloxacin (Watch category) - only if local resistance data permits 1
• Second choice: Ceftriaxone or cefotaxime (Watch category) 1

Severe cases:

• First choice: Ceftriaxone or cefotaxime (Watch category) 1
• Second choice: Amikacin (Access category) - preferred over gentamicin due to better activity against Enterobacterales, particularly ESBL-producing strains 1

Intra-abdominal Infections

Mild-to-moderate:

• First choice: Amoxicillin-clavulanate OR ampicillin + gentamicin + metronidazole (in children) 1
• Second choice: Ciprofloxacin + metronidazole OR cefotaxime/ceftriaxone + metronidazole 1

Severe:

• First choice: Cefotaxime or ceftriaxone + metronidazole OR piperacillin-tazobactam 1
• Second choice: Ampicillin + gentamicin + metronidazole OR meropenem 1

Bloodstream Infections/Sepsis

For community-acquired infections with ESBL-negative E. coli, third-generation cephalosporins remain appropriate 2. However, with 46-54% ESBL prevalence in many settings 3, 2, empiric therapy must account for local resistance patterns.

For ESBL-producing strains:

• Carbapenems (imipenem, meropenem, ertapenem) remain the mainstay with 99.3% susceptibility 2
• Piperacillin-tazobactam shows 92.3% susceptibility 2
• Amikacin demonstrates 98.3% susceptibility 2

Multidrug-Resistant and Carbapenem-Resistant E. coli

For carbapenem-resistant E. coli (CRE):

Monotherapy options when susceptible:

• Ceftazidime-avibactam (94.3% susceptibility) 4
• Meropenem-vaborbactam
• Cefiderocol

5, 6, 4

Do NOT use combination therapy if the organism is susceptible to these newer agents 5.

For severe infections with metallo-β-lactamase (MBL) producers:

• Aztreonam + ceftazidime-avibactam combination (conditional recommendation) 5, 6

For CRE susceptible only to older agents:

• Use combination therapy with more than one active drug (polymyxins, aminoglycosides, tigecycline, or fosfomycin) 5
• Tigecycline shows 99.8% susceptibility 2
• Avoid carbapenem-based combinations unless meropenem MIC ≤8 mg/L, where high-dose extended-infusion meropenem may be considered 5

Special Considerations

Enterohemorrhagic E. coli (EHEC/STEC including O157:H7):

Do NOT use antibiotics for EHEC infections - particularly avoid DNA synthesis inhibitors (fluoroquinolones, trimethoprim-sulfamethoxazole) as they increase Shiga toxin release and HUS risk 7, 8. Some evidence suggests protein and cell wall synthesis inhibitors may be safer if treatment is absolutely necessary, but supportive care remains the standard 7, 8.

Enteropathogenic E. coli (EPEC) gastroenteritis:

Antibiotics are beneficial for severe endemic infantile diarrhea caused by EPEC. Historical data shows 79% clinical cure with mecillinam and 73% with trimethoprim-sulfamethoxazole versus 7% in untreated controls 9.

Key Clinical Pitfalls

1. Never use plain amoxicillin for empiric UTI treatment - resistance exceeds 75% globally 1

2. Avoid quinolones for simple cystitis - reserve for pyelonephritis where benefits justify FDA-warned risks 1

3. ESBL prevalence is 46-54% in many regions - if suspected, avoid third-generation cephalosporins and consider piperacillin-tazobactam or carbapenems 3, 2

4. Hospital-acquired infections have higher ESBL rates and require broader coverage - median hospitalization 30 days versus 10 days for community-acquired 2

5. De-escalate therapy once susceptibilities are known - starting broad and narrowing reduces hospitalization without compromising outcomes 2

6. For CRE, newer β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol) should be used as monotherapy when susceptible - combination therapy only for severe infections or MBL producers 5